<?xml version='1.0' encoding='utf-8'?>
<document id="28815028"><sentence text="The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions." /><sentence text="Direct-acting antivirals have improved treatment of chronic hepatitis C virus infection significantly" /><sentence text=" Direct-acting antivirals inhibit/induce and can also be substrates of drug-metabolising enzymes and transporters" /><sentence text=" This increases the risk for drug-drug interactions" /><sentence text="" /><sentence text="The purpose of this study was to predict drug-drug interactions with co-medication used by hepatitis C virus-infected patients" /><sentence text="" /><sentence text="We assembled a nationwide cohort of hepatitis C patients and collected cross-sectional data on co-medication use" /><sentence text=" We compiled a list of currently available direct-acting antiviral regimens and cross-checked for potential drug-drug interactions with used co-medication" /><sentence text="" /><sentence text="The cohort included 461 patients of which 77% used co-medication" /><sentence text=" We identified 260 drugs used as co-medication" /><sentence text=" Antidepressants (7" /><sentence text="4%), proton pump inhibitors (7" /><sentence text="1%) and benzodiazepines (7"><entity charOffset="8-23" id="DDI-PubMed.28815028.s15.e0" text="benzodiazepines" /></sentence><sentence text="1%) were most frequently used" /><sentence text=" Of the patients, 60% were at risk for a clinically relevant drug-drug interaction with at least one of the direct-acting antiviral regimens" /><sentence text=" Interactions were most common with paritaprevir/ritonavir/ombitasvir/dasabuvir and least interactions were predicted with grazoprevir/elbasvir"><entity charOffset="36-48" id="DDI-PubMed.28815028.s18.e0" text="paritaprevir" /><entity charOffset="49-58" id="DDI-PubMed.28815028.s18.e1" text="ritonavir" /><entity charOffset="59-69" id="DDI-PubMed.28815028.s18.e2" text="ombitasvir" /><entity charOffset="70-79" id="DDI-PubMed.28815028.s18.e3" text="dasabuvir" /><entity charOffset="123-134" id="DDI-PubMed.28815028.s18.e4" text="grazoprevir" /><entity charOffset="135-143" id="DDI-PubMed.28815028.s18.e5" text="elbasvir" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e2" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e3" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e4" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e0" e2="DDI-PubMed.28815028.s18.e5" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e1" e2="DDI-PubMed.28815028.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e1" e2="DDI-PubMed.28815028.s18.e2" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e1" e2="DDI-PubMed.28815028.s18.e3" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e1" e2="DDI-PubMed.28815028.s18.e4" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e1" e2="DDI-PubMed.28815028.s18.e5" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e2" e2="DDI-PubMed.28815028.s18.e2" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e2" e2="DDI-PubMed.28815028.s18.e3" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e2" e2="DDI-PubMed.28815028.s18.e4" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e2" e2="DDI-PubMed.28815028.s18.e5" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e3" e2="DDI-PubMed.28815028.s18.e3" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e3" e2="DDI-PubMed.28815028.s18.e4" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e3" e2="DDI-PubMed.28815028.s18.e5" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e4" e2="DDI-PubMed.28815028.s18.e4" /><pair ddi="false" e1="DDI-PubMed.28815028.s18.e4" e2="DDI-PubMed.28815028.s18.e5" /></sentence><sentence text="" /><sentence text="Co-medication use is rich in frequency and diversity in chronic hepatitis C patients" /><sentence text=" The majority of patients are at risk for drug-drug interactions which may affect efficacy or toxicity of direct-acting antivirals or co-medication" /><sentence text=" The most recently introduced direct-acting antivirals are associated with a lower risk of drug-drug interactions" /><sentence text="" /></document>